Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
BCR-ABL1-negative myeloproliferative neoplasms are burdened by a reduced life expectancy mostly due to an increased risk of thrombo-hemorrhagic events, fibrotic progression/leukemic evolution, and infectious complications. In these clonal myeloid malignancies, JAK2V617F is the main driver mutation,...
Guardado en:
Autores principales: | Daniele Cattaneo, Alessandra Iurlo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0387f2811bc4960a7bb65e2a6fc62db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploring redox vulnerabilities in JAK2V617F-positive cellular models
por: Keli Lima, et al.
Publicado: (2021) -
Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
por: Lukas M. Braun, et al.
Publicado: (2021) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi K, et al.
Publicado: (2016) -
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Giulia Radi, et al.
Publicado: (2021) -
Molecular basis of essential thrombocythaemia in humans and dogs – a review
por: Nicola Padzik, et al.
Publicado: (2021)